Merck and Acceleron Pharma have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion. The transaction is expected to close in the fourth quarter of 2021. Acceleron is focused on harnessing the power of the […]

Laronde, the Cambridge startup pioneering a novel, engineered form of RNA they call Endless RNA™ (eRNA), has raised $440 Million in a Series B Financing. eRNA can be programmed to express therapeutic proteins inside the body. The financing round included the company’s founder, Flagship Pioneering, among other investors. Ribonucleic acids, or RNAs, play a significant role in biology. […]

Vertex Pharmaceuticals and Arbor Biotechnologies have announced a new collaboration to enhance efforts in developing ex vivo engineered cell therapies using Arbor’s proprietary CRISPR gene-editing technology for select diseases. The new agreement builds upon the companies’ first partnership established in 2018. Under this new partnership, Vertex will receive rights to use Arbor’s technology to research and develop ex […]